NorthStar Medical Radioisotopes will supply biotech company Ariceum Therapeutics with actinium-225 (Ac-225) for the development of radiopharmaceuticals for cancer diagnosis and treatment.
Ariceum will use NorthStar’s Ac-225 to radiolabel its proprietary peptide satoreotide, which targets somatostatin receptor 2 (SSTR2) on cancer cells. Satoreotide is being developed as a theranostic pair for the combined diagnosis and targeted radionuclide treatment of multiple indications expressing SSTR2, such as small cell lung cancer, pancreatic cancers, Merkel Cell Carcinoma, and other aggressive cancers, NorthStar said.
Ariceum is a Berlin-based company launched in 2021 whose name is an anagram of “Marie Curie,” NorthStar noted.
